<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/eyepoint-pharmaceuticals-inc-logo-1200x675.png/query-dj0yMDIyMTIyMjE1NTAyNA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/eyepoint-pharmaceuticals-inc-logo-1200x675.png/query-dj0yMDIyMTIyMjE1NTAyNA"/></p>
<p>EyePoint Pharmaceuticals, Inc.（NASDAQ：EYPT）股票在週一的午盤交易中下跌了 6.4%。股價最低跌至 9.96 美元，最後交易價為 10.02 美元。交易中約有 436,621 股股票交易，較平均日交易量 1,101,198 股下降了 60%。該股票上一個收盤價為 10.71 美元。</p>
<h2>分析師評級變動</h2>
<p>EYPT 已成為多份研究報告的主題。Chardan Capital 將 EyePoint Pharmaceuticals 的目標股價從 39.00 美元降至 28.00 美元，並在 5 月 7 日星期二的一份報告中為該股票設定了 “買入” 評級。Robert W. Baird 將 EyePoint Pharmaceuticals 的目標股價從 46.00 美元降至 38.00 美元，並在 5 月 8 日星期三的一份報告中為該股票設定了 “表現優異” 評級。Capital One Financial 在 2 月 16 日星期五的一份報告中重申了對 EyePoint Pharmaceuticals 股票的 “超重” 評級。Mizuho 將 EyePoint Pharmaceuticals 的目標股價從 39.00 美元降至 30.00 美元，並在 5 月 7 日星期二的一份報告中為該股票設定了 “買入” 評級。最後，StockNews.com 在 5 月 9 日星期四的一份報告中，將 EyePoint Pharmaceuticals 的評級從 “持有” 降至 “賣出”。一位投資分析師對該股票進行了賣出評級，七位分析師為該公司給出了買入評級。根據 MarketBeat 的數據，該股票的共識評級為 “中等買入”，共識目標股價為 33.71 美元。</p>
<p><strong>查看我們對 EyePoint Pharmaceuticals 的最新股票分析</strong></p>
<h2>EyePoint Pharmaceuticals 股票表現</h2>
<p>該股票的 50 天移動平均股價為 16.50 美元，200 天移動平均股價為 19.82 美元。該公司的市值為 5.1455 億美元，市盈率為-5.45，貝塔係數為 1.59。</p>
<p>EyePoint Pharmaceuticals（NASDAQ：EYPT）上次公佈季度財報是在 5 月 8 日星期三。公司報告該季度每股收益（EPS）為（0.55）美元，低於分析師預期的（0.34）美元。EyePoint Pharmaceuticals 的淨利潤率為-157.77%，淨資產收益率為-49.94%。該季度公司的營收為 1,168 萬美元，低於分析師預期的 1,250 萬美元。分析師預計 EyePoint Pharmaceuticals, Inc.今年將實現每股盈利-2.14 美元。</p>
<h2>內部交易活動</h2>
<p>據報道，董事 David R. Guyer 於 5 月 14 日星期二出售了 11,625 股 EyePoint Pharmaceuticals 股票。這些股票的平均售價為 12.65 美元，總交易額為 147,056.25 美元。交易完成後，該董事在公司中直接持有 5,550 股股票，價值約 70,207.50 美元。該交易已在美國證券交易委員會（SEC）的法律文件中披露，可通過此超鏈接查看。此外，董事 David R. Guyer 還於 5 月 14 日星期二另一次出售了 11,625 股 EyePoint Pharmaceuticals 股票。這些股票的平均售價為 12.65 美元，總交易額為 147,056.25 美元。交易完成後，該董事在公司中直接持有 5,550 股股票，價值約 70,207.50 美元。該交易已在美國證券交易委員會（SEC）的法律文件中披露，可在 SEC 網站上找到。此外，主要股東 Cormorant Asset Management, Lp 於 5 月 6 日星期一以每股 11.86 美元的平均價格收購了該公司的 850,000 股股票，總價值為 10,081,000.00 美元。交易完成後，該內部人士在公司中直接持有 8,325,000 股股票，價值 98,734,500 美元。有關此次購買的披露可在此處找到。內部人士持有該公司的股份的比例為 4.74%。</p>
<h2>EyePoint Pharmaceuticals 的機構交易</h2>
<p>對沖基金和其他機構投資者最近已買入和賣出了該公司的股票。FNY Investment Advisers LLC 在第四季度購入了 EyePoint Pharmaceuticals 的新股份，價值約 27,000 美元。Ameritas Investment Partners Inc.在第一季度將其對 EyePoint Pharmaceuticals 的持股增加了 44.0%，現在擁有 3,719 股該公司股票，價值 77,000 美元，較之前增加了 1,136 股。China Universal Asset Management Co. Ltd.在第四季度購入了 EyePoint Pharmaceuticals 的新股份，價值 94,000 美元。Sherbrooke Park Advisers LLC 在第三季度購入了 EyePoint Pharmaceuticals 的新股份，價值 101,000 美元。最後，Tower Research Capital LLC TRC 在第四季度將其對 EyePoint Pharmaceuticals 的持股增加了 36.0%，現在擁有 4,724 股該公司股票，價值 109,000 美元，較之前增加了 1,250 股。99.41% 的股份由對沖基金和其他機構投資者持有。</p>
<h2>關於 EyePoint Pharmaceuticals（獲取免費報告）</h2>
<p>EyePoint Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，致力於開發和商業化治療嚴重視網膜疾病患者生活的藥物。該公司的產品線利用其專有的可生物降解的 Durasert E 技術，用於持續眼內藥物釋放。</p>
<h2>參見</h2>
<ul>
<li>我們喜歡的五隻股票，比 EyePoint Pharmaceuticals 更好</li>
<li>在購買股票之前如何評估一家公司</li>
<li>為什麼 Smartsheet 股票是被低估的投資寶石</li>
<li>為什麼投資 5G？如何投資 5G 股票</li>
<li>Q1 季度財報後最受推崇的股票</li>
<li>技術指標如何幫助您找到被超賣的股票</li>
<li>什麼是風險承受能力，為什麼它很重要？</li>
</ul>
<p><em>這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成的，旨在為讀者提供最快速和最準確的報道。在發佈之前，這則故事已經經過 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 必看：埃隆的新發明絕對瘋狂（來自 InvestorPlace）(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MDg3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MDg3"/></p>
<h2>現在是否值得投資 EyePoint Pharmaceuticals $1,000？</h2>
<p>在考慮投資 EyePoint Pharmaceuticals 之前，您應該聽聽這個。</p>
<p>MarketBeat 追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該買入的股票...而 EyePoint Pharmaceuticals 並不在名單上。</p>
<p>雖然 EyePoint Pharmaceuticals 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

納斯達克 OMX 交易所

EYPT

<p>眼點製藥（NASDAQ：EYPT）股票在午間交易中下跌了 6.4%，交易量也有所下降。分析師已經調低了該股的價格目標，公司最近的財報顯示淨利潤率為負。內部人士的交易活動包括一位董事出售股份和一位主要股東增持股份。對沖基金和機構投資者也一直在買賣股份。該股票的 50 天移動平均價為 16.50 美元</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/eyepoint-pharmaceuticals-inc-logo-1200x675.png/query-dj0yMDIyMTIyMjE1NTAyNA" alt="" original-src="https://www.marketbeat.com/logos/eyepoint-pharmaceuticals-inc-logo-1200x675.png?v=20221222155024"/></p>
<p>Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) dropped 6.4% during mid-day trading on Monday . The stock traded as low as $9.96 and last traded at $10.02. Approximately 436,621 shares were traded during trading, a decline of 60% from the average daily volume of 1,101,198 shares. The stock had previously closed at $10.71.</p>
<div class="lb-trans"><p>EyePoint Pharmaceuticals, Inc.（NASDAQ：EYPT）股票在週一的午盤交易中下跌了 6.4%。股價最低跌至 9.96 美元，最後交易價為 10.02 美元。交易中約有 436,621 股股票交易，較平均日交易量 1,101,198 股下降了 60%。該股票上一個收盤價為 10.71 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>EYPT has been the topic of several research reports. Chardan Capital dropped their price objective on EyePoint Pharmaceuticals from $39.00 to $28.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday, May 7th. Robert W. Baird lowered their price target on EyePoint Pharmaceuticals from $46.00 to $38.00 and set an &#34;outperform&#34; rating on the stock in a report on Wednesday, May 8th. Capital One Financial reissued an &#34;overweight&#34; rating on shares of EyePoint Pharmaceuticals in a report on Friday, February 16th. Mizuho lowered their price target on EyePoint Pharmaceuticals from $39.00 to $30.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday, May 7th. Finally, StockNews.com lowered EyePoint Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Thursday, May 9th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $33.71.</p>
<div class="lb-trans"><p>EYPT 已成為多份研究報告的主題。Chardan Capital 將 EyePoint Pharmaceuticals 的目標股價從 39.00 美元降至 28.00 美元，並在 5 月 7 日星期二的一份報告中為該股票設定了 “買入” 評級。Robert W. Baird 將 EyePoint Pharmaceuticals 的目標股價從 46.00 美元降至 38.00 美元，並在 5 月 8 日星期三的一份報告中為該股票設定了 “表現優異” 評級。Capital One Financial 在 2 月 16 日星期五的一份報告中重申了對 EyePoint Pharmaceuticals 股票的 “超重” 評級。Mizuho 將 EyePoint Pharmaceuticals 的目標股價從 39.00 美元降至 30.00 美元，並在 5 月 7 日星期二的一份報告中為該股票設定了 “買入” 評級。最後，StockNews.com 在 5 月 9 日星期四的一份報告中，將 EyePoint Pharmaceuticals 的評級從 “持有” 降至 “賣出”。一位投資分析師對該股票進行了賣出評級，七位分析師為該公司給出了買入評級。根據 MarketBeat 的數據，該股票的共識評級為 “中等買入”，共識目標股價為 33.71 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on EyePoint Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們對 EyePoint Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>EyePoint Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>EyePoint Pharmaceuticals 股票表現</h2>
</div><p>The stock's 50-day moving average price is $16.50 and its 200-day moving average price is $19.82. The company has a market capitalization of $514.55 million, a price-to-earnings ratio of -5.45 and a beta of 1.59.</p>
<div class="lb-trans"><p>該股票的 50 天移動平均股價為 16.50 美元，200 天移動平均股價為 19.82 美元。該公司的市值為 5.1455 億美元，市盈率為-5.45，貝塔係數為 1.59。</p>
</div><p>EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.21). EyePoint Pharmaceuticals had a negative net margin of 157.77% and a negative return on equity of 49.94%. The company had revenue of $11.68 million for the quarter, compared to analyst estimates of $12.50 million. Analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.14 earnings per share for the current year.</p>
<div class="lb-trans"><p>EyePoint Pharmaceuticals（NASDAQ：EYPT）上次公佈季度財報是在 5 月 8 日星期三。公司報告該季度每股收益（EPS）為（0.55）美元，低於分析師預期的（0.34）美元。EyePoint Pharmaceuticals 的淨利潤率為-157.77%，淨資產收益率為-49.94%。該季度公司的營收為 1,168 萬美元，低於分析師預期的 1,250 萬美元。分析師預計 EyePoint Pharmaceuticals, Inc.今年將實現每股盈利-2.14 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部交易活動</h2>
</div><p>In other news, Director David R. Guyer sold 11,625 shares of EyePoint Pharmaceuticals stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $12.65, for a total transaction of $147,056.25. Following the completion of the sale, the director now directly owns 5,550 shares in the company, valued at approximately $70,207.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director David R. Guyer sold 11,625 shares of EyePoint Pharmaceuticals stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $12.65, for a total transaction of $147,056.25. Following the completion of the transaction, the director now directly owns 5,550 shares in the company, valued at approximately $70,207.50. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, major shareholder Cormorant Asset Management, Lp acquired 850,000 shares of the business's stock in a transaction that occurred on Monday, May 6th. The shares were bought at an average price of $11.86 per share, with a total value of $10,081,000.00. Following the completion of the transaction, the insider now directly owns 8,325,000 shares in the company, valued at $98,734,500. The disclosure for this purchase can be found here. Insiders own 4.74% of the company's stock.</p>
<div class="lb-trans"><p>據報道，董事 David R. Guyer 於 5 月 14 日星期二出售了 11,625 股 EyePoint Pharmaceuticals 股票。這些股票的平均售價為 12.65 美元，總交易額為 147,056.25 美元。交易完成後，該董事在公司中直接持有 5,550 股股票，價值約 70,207.50 美元。該交易已在美國證券交易委員會（SEC）的法律文件中披露，可通過此超鏈接查看。此外，董事 David R. Guyer 還於 5 月 14 日星期二另一次出售了 11,625 股 EyePoint Pharmaceuticals 股票。這些股票的平均售價為 12.65 美元，總交易額為 147,056.25 美元。交易完成後，該董事在公司中直接持有 5,550 股股票，價值約 70,207.50 美元。該交易已在美國證券交易委員會（SEC）的法律文件中披露，可在 SEC 網站上找到。此外，主要股東 Cormorant Asset Management, Lp 於 5 月 6 日星期一以每股 11.86 美元的平均價格收購了該公司的 850,000 股股票，總價值為 10,081,000.00 美元。交易完成後，該內部人士在公司中直接持有 8,325,000 股股票，價值 98,734,500 美元。有關此次購買的披露可在此處找到。內部人士持有該公司的股份的比例為 4.74%。</p>
</div><h2>Institutional Trading of EyePoint Pharmaceuticals</h2>
<div class="lb-trans"><h2>EyePoint Pharmaceuticals 的機構交易</h2>
</div><p>Hedge funds and other institutional investors have recently bought and sold shares of the company. FNY Investment Advisers LLC purchased a new stake in EyePoint Pharmaceuticals in the 4th quarter worth approximately $27,000. Ameritas Investment Partners Inc. grew its stake in shares of EyePoint Pharmaceuticals by 44.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,719 shares of the company's stock valued at $77,000 after buying an additional 1,136 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in shares of EyePoint Pharmaceuticals during the 4th quarter valued at $94,000. Sherbrooke Park Advisers LLC purchased a new stake in shares of EyePoint Pharmaceuticals during the 3rd quarter valued at $101,000. Finally, Tower Research Capital LLC TRC grew its stake in shares of EyePoint Pharmaceuticals by 36.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,724 shares of the company's stock valued at $109,000 after buying an additional 1,250 shares during the period. 99.41% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近已買入和賣出了該公司的股票。FNY Investment Advisers LLC 在第四季度購入了 EyePoint Pharmaceuticals 的新股份，價值約 27,000 美元。Ameritas Investment Partners Inc.在第一季度將其對 EyePoint Pharmaceuticals 的持股增加了 44.0%，現在擁有 3,719 股該公司股票，價值 77,000 美元，較之前增加了 1,136 股。China Universal Asset Management Co. Ltd.在第四季度購入了 EyePoint Pharmaceuticals 的新股份，價值 94,000 美元。Sherbrooke Park Advisers LLC 在第三季度購入了 EyePoint Pharmaceuticals 的新股份，價值 101,000 美元。最後，Tower Research Capital LLC TRC 在第四季度將其對 EyePoint Pharmaceuticals 的持股增加了 36.0%，現在擁有 4,724 股該公司股票，價值 109,000 美元，較之前增加了 1,250 股。99.41% 的股份由對沖基金和其他機構投資者持有。</p>
</div><h2>About EyePoint Pharmaceuticals (Get Free Report)</h2>
<div class="lb-trans"><h2>關於 EyePoint Pharmaceuticals（獲取免費報告）</h2>
</div><p>EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.</p>
<div class="lb-trans"><p>EyePoint Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，致力於開發和商業化治療嚴重視網膜疾病患者生活的藥物。該公司的產品線利用其專有的可生物降解的 Durasert E 技術，用於持續眼內藥物釋放。</p>
</div><h2>See Also</h2>
<ul>
<li>Five stocks we like better than EyePoint Pharmaceuticals</li>
<li>How to Evaluate a Stock Before Buying</li>
<li>Why Smartsheet Stock is an Undervalued Gem of an Investment</li>
<li>Why Invest in 5G? How to Invest in 5G Stocks</li>
<li>The Most Upgraded Stocks After the Q1 Earnings Season</li>
<li>How Technical Indicators Can Help You Find Oversold Stocks</li>
<li>What Is Risk Tolerance &amp; Why Is It Important?</li>
</ul>
<div class="lb-trans"><h2>參見</h2>
<ul>
<li>我們喜歡的五隻股票，比 EyePoint Pharmaceuticals 更好</li>
<li>在購買股票之前如何評估一家公司</li>
<li>為什麼 Smartsheet 股票是被低估的投資寶石</li>
<li>為什麼投資 5G？如何投資 5G 股票</li>
<li>Q1 季度財報後最受推崇的股票</li>
<li>技術指標如何幫助您找到被超賣的股票</li>
<li>什麼是風險承受能力，為什麼它很重要？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成的，旨在為讀者提供最快速和最準確的報道。在發佈之前，這則故事已經經過 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace)(Ad)</p>
<div class="lb-trans"><p>→ 必看：埃隆的新發明絕對瘋狂（來自 InvestorPlace）(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MDg3" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8087&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in EyePoint Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資 EyePoint Pharmaceuticals $1,000？</h2>
</div><p>Before you consider EyePoint Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 EyePoint Pharmaceuticals 之前，您應該聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該買入的股票...而 EyePoint Pharmaceuticals 並不在名單上。</p>
</div><p>While EyePoint Pharmaceuticals currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 EyePoint Pharmaceuticals 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

EyePoint Pharmaceuticals（納斯達克：EYPT）股價下跌 6.4%